Don’t miss out on the next big thing in the life sciences.

Joseph Tucker, Ph.D., CEO & Director, Enveric Biosciences

In this Q&A, Tucker explains what set Enveric apart from the first wave of psychedelic biotech companies: rather than rushing traditional molecules into the clinic, the team chose to do the harder medicinal chemistry work — designing non-hallucinogenic compounds that might deliver the therapeutic benefits of psychedelic-inspired pharmacology without the practical barriers that limit scalability. He discusses the science behind EB-003, Enveric's lead candidate; the company's path toward an IND and first-in-human trial; how Cambridge's life sciences ecosystem supports that mission; and why he believes the convergence of scientific rigor and growing policy recognition makes this a genuine inflection point for neuropsychiatric medicine.